Semin Thromb Hemost 2000; Volume 26(Number 01): 029-032
DOI: 10.1055/s-2000-9799
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 760-0888

Current Status of Hemophilia Patients and Recombinant Coagulation Factor Concentrates in Japan

Katsuyuki Fukutake
  • Supported by Health Sciences Research Grants on HIV/AIDS, Ministry of Health and Welfare. Department of Clinical Pathology, Tokyo Medical University, Tokyo, Japan
Further Information

Publication History

Publication Date:
31 December 2000 (online)

 

ABSTRACT

The first recombinant factor VIII concentrate was introduced in 1987 to treat hemophilia A patients, and the product was licensed in the United States in 1992. More than 10 years have passed since the recombinant products have been used for treatment of hemophilia A. The new therapeutic options seem to be safe and effective through the gathered experiences. Recently, recombinant factor VIIa concentrate has become available to treat hemophilia patients with inhibitor and factor VII deficiency patients in Europe and also recombinant factor IX for the treatment of hemophilia B has been licensed in the United States and Europe. The usage of recombinant coagulation factors has expanded the routine therapy for hemophilia in many countries.

In Japan, the consumption of recombinant factor VIII is increasing year by year, because many patients have started to think that the recombinant technology seems to be safe. Unfortunately, though, the factor VIIa and factor IX products have not been licensed yet in Japan. This article discusses the current status of patients with hemophilia and recombinant coagulation factor products in Japan.

KEYWORD

Hemophilia - recombinant coagulation factor concentrate - factor VIII - factor VIIa - factor IX

REFERENCES

  • 1 Bray G L, Gomperts E D, Courter S. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A.  Blood . 1994;  83 2428-2435
    PubMedSearch in Google Scholar
  • 2 Lusher J M, Arkin S, Abildgaard C P. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A.  N Engl J Med . 1993;  328 453-459
    CrossrefPubMedSearch in Google Scholar
  • 3 Schmit M L, Gamerman S, Smith H E. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors.  Am J Hematol . 1994;  47 36-40
    PubMedSearch in Google Scholar
  • 4 Keith J C, Ferranti T J, Misra B. Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog.  Thromb Haemost . 1995;  73 101-105
    PubMedSearch in Google Scholar
  • 5 Brettler D B. Recombinant coagulation factor products.  Haemophilia . 1995;  1 155-158
    PubMedSearch in Google Scholar